Avalo Therapeutics, Inc. · NASDAQ:AVTX

Sullivan Christopher Ryan sold 12,394 Avalo Therapeutics, Inc. shares (Form 4)

Traded Sep 16, 2026 · Filed Sep 18, 2026

On Sep 16, 2026, Sullivan Christopher Ryan (Chief Financial Officer) sold 12,394 Avalo Therapeutics, Inc. shares at US$16.33 for US$202K under a trading plan, leaving 39,900 shares. Filed Sep 18, 2026 (Form 4).

Sold
12,394 shares
Price
US$16.33
Value
US$202K
Holding after
39,900 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Sep 16, 2026Common StockOption exercise12,394US$9.8852,294Direct
Sep 16, 2026Common StockSale12,394US$16.3339,900Direct

Source

View original at SEC

Related